| Not Yet Recruiting | FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma NCT07446777 | University of Miami | N/A |
| Not Yet Recruiting | Clonal Hematopoiesis of Immunological Significance NCT05969821 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patient NCT07305662 | Seoul National University Bundang Hospital | N/A |
| Withdrawn | Daratumumab for Polyneuropathy Associated With MGUS NCT06046287 | Georgetown University | Phase 2 |
| Not Yet Recruiting | Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS NCT06559033 | University Hospital, Rouen | — |
| Not Yet Recruiting | Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technol NCT06489613 | Jian Li | — |
| Enrolling By Invitation | MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study NCT06472830 | Mayo Clinic | — |
| Recruiting | Whole Body MRI in Oncology NCT06895291 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Recruiting | A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Mono NCT06055894 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study NCT05965115 | Shanghai Zhongshan Hospital | — |
| Active Not Recruiting | Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program NCT05831358 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Promoting Diagnosis and Management of AL in Italy (ProDigALIty) NCT06383143 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Unde NCT05640843 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor C NCT05361694 | University of Miami | — |
| Recruiting | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Ca NCT04731844 | University of Rochester | Phase 2 |
| Unknown | Isatuximab in Type I Cryoglobulinemia NCT05114109 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Not Yet Recruiting | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory He NCT04702932 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smol NCT04920084 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma NCT04850846 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey NCT04727294 | HealthTree Foundation | — |
| Completed | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization NCT04439006 | Jennifer Woyach | Phase 1 |
| Completed | Screening to Improve Survival in AL Amyloidosis NCT04615572 | Tufts Medical Center | — |
| Recruiting | Sleep Apnea in Patients With MGUS and MM NCT04114084 | Michael Tomasson | — |
| Completed | Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery NCT03855878 | Indiana University | — |
| Completed | Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma NCT03119883 | Mayo Clinic | N/A |
| Active Not Recruiting | Iceland Screens, Treats or Prevents Multiple Myeloma NCT03327597 | University of Iceland | N/A |
| Recruiting | Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807 | M.D. Anderson Cancer Center | — |
| Recruiting | Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma NCT02726750 | M.D. Anderson Cancer Center | — |
| Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry NCT02298816 | Wake Forest University Health Sciences | — |
| Completed | Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma NCT01955395 | Dana-Farber Cancer Institute | N/A |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Imaging Studies and the Development of Multiple Myeloma NCT01571726 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource NCT01408225 | Ohio State University Comprehensive Cancer Center | — |
| Completed | Imaging in MGUS, SMM and MM NCT01237054 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermin NCT01219010 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM NCT01109407 | National Cancer Institute (NCI) | — |
| Terminated | Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM NCT01079429 | Rennes University Hospital | — |
| Terminated | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) NCT00899353 | Marshall University | Phase 2 |
| Completed | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma NCT00099047 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. NCT00919139 | SWOG Cancer Research Network | — |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |